Samalin Investment Counsel’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $482K | Buy |
6,979
+372
| +6% | +$25.7K | 0.18% | 176 |
|
|
2025
Q1 | $459K | Sell |
6,607
-452
| -6% | -$31.4K | 0.19% | 170 |
|
|
2024
Q4 | $607K | Sell |
7,059
-470
| -6% | -$40.4K | 0.26% | 109 |
|
|
2024
Q3 | $896K | Sell |
7,529
-475
| -6% | -$56.6K | 0.39% | 65 |
|
|
2024
Q2 | $1.14M | Buy |
8,004
+7
| +0.1% | +$999 | 0.53% | 45 |
|
|
2024
Q1 | $1.03M | Buy |
7,997
+126
| +2% | +$16.2K | 0.49% | 53 |
|
|
2023
Q4 | $814K | Sell |
7,871
-241
| -3% | -$24.9K | 0.41% | 68 |
|
|
2023
Q3 | $738K | Sell |
8,112
-84
| -1% | -$7.64K | 0.42% | 69 |
|
|
2023
Q2 | $663K | Sell |
8,196
-2
| -0% | -$162 | 0.36% | 74 |
|
|
2023
Q1 | $652K | Buy |
8,198
+36
| +0.4% | +$2.87K | 0.39% | 71 |
|
|
2022
Q4 | $552K | Sell |
8,162
-396
| -5% | -$26.8K | 0.35% | 86 |
|
|
2022
Q3 | $426K | Sell |
8,558
-158
| -2% | -$7.87K | 0.31% | 96 |
|
|
2022
Q2 | $486K | Buy |
8,716
+102
| +1% | +$5.69K | 0.34% | 84 |
|
|
2022
Q1 | $478K | Hold |
8,614
| – | – | 0.29% | 102 |
|
|
2021
Q4 | $482K | Sell |
8,614
-30
| -0.3% | -$1.68K | 0.29% | 100 |
|
|
2021
Q3 | $415K | Buy |
8,644
+312
| +4% | +$15K | 0.27% | 119 |
|
|
2021
Q2 | $349K | Sell |
8,332
-94
| -1% | -$3.94K | 0.23% | 158 |
|
|
2021
Q1 | $284K | Sell |
8,426
-44
| -0.5% | -$1.48K | 0.19% | 176 |
|
|
2020
Q4 | $296K | Sell |
8,470
-194
| -2% | -$6.78K | 0.22% | 157 |
|
|
2020
Q3 | $301K | Buy |
8,664
+236
| +3% | +$8.2K | 0.27% | 121 |
|
|
2020
Q2 | $275K | Sell |
8,428
-8,388
| -50% | -$274K | 0.29% | 114 |
|
|
2020
Q1 | $506K | Sell |
16,816
-100
| -0.6% | -$3.01K | 0.68% | 43 |
|
|
2019
Q4 | $489K | Buy |
+16,916
| New | +$489K | 0.41% | 63 |
|